Phaseline

Companies › Samuel Fortin

Samuel Fortin: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Psychiatry; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Monoglyceride Eicosapentaenoic acid (MAG-EPA)
Omega-3 fatty acid that activates free fatty acid receptors and reduces inflammation throu
FFAR1, FFAR4Phase 4Brain FogMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06695910Monoglyceride Eicosapentaenoic acid (MAG-EPA)Phase 4Brain FogPsychiatryMay 2027

Targets

FFAR1 (1) FFAR4 (1)

Companies with the same targets

–

Companies built like this

ProofPilot Oui Therapeutics Taysha Gene Therapies Gedeon Richter Biomed Industries

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.